Pharmaceutical

Tris Pharma receives ex-US approvals for ADHD treatments

Tris Pharma has received additional ex-US approvals for its ADHD treatments, Quillivant XR and QuilliChew ER.

Nov 21, 2024 - 06:00
Tris Pharma receives ex-US approvals for ADHD treatments
Tris Pharma has received additional ex-US approvals for its ADHD treatments, Quillivant XR and QuilliChew ER.
Read the original article

Tags:

Previous Article

KM Biologics’ mpox vaccine approved for emergency use by WHO

Next Article

Veeva Commercial Summit: Increased investment in medical affairs by pharma compa...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Asahi Kasei offers to buy Sweden’s Calliditas for $1.04bn

Asahi Kasei offers to buy Sweden’s Calliditas for $1.04bn

May 29, 2024

Why depression after traumatic brain injury is distinct — and less likely to respond to standard treatment

Why depression after traumatic brain injury is distinct...

Jul 6, 2023

Santhera’s DMD therapy Agamree approved for NHS use after new price deal

Santhera’s DMD therapy Agamree approved for NHS use aft...

Dec 11, 2024